Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
In recent years, anti-tumor immunotherapies have witnessed a major breakthrough with the emergence of immune checkpoint inhibitors (ICIs). However, the use of ICIs has also brought an era of a certain class of adverse events that differ from those of classical chemotherapies and are more reminiscent...
Saved in:
Main Authors: | Carmen Portenkirchner (Author), Peter Kienle (Author), Karoline Horisberger (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
by: Wang S, et al.
Published: (2024) -
An overview of immune checkpoint inhibitors in breast cancer
by: Federica Miglietta, et al.
Published: (2020) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020) -
[Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
by: G. Juan-Carpena, et al.
Published: (2022) -
Nephrotoxicity of checkpoint inhibitors; a current challenge
by: Samaneh Zandifar, et al.
Published: (2024)